Elevance Health (NYSE:ELV) Price Target Raised to $357.00

Elevance Health (NYSE:ELV) had its price target increased by Leerink Partners from $350.00 to $357.00 in a research report report published on Thursday,MarketScreener reports. Leerink Partners currently has a market perform rating on the stock.

A number of other brokerages also recently issued reports on ELV. Truist Financial set a $400.00 price target on Elevance Health in a research report on Tuesday, October 14th. Guggenheim reduced their target price on Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a research note on Thursday. Zacks Research upgraded Elevance Health from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 6th. JPMorgan Chase & Co. lifted their price target on shares of Elevance Health from $384.00 to $394.00 and gave the company an “overweight” rating in a research note on Tuesday, October 28th. Finally, Barclays reduced their price objective on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a research report on Friday. Thirteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Elevance Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $396.90.

Elevance Health Stock Down 0.4%

Shares of ELV stock opened at $345.62 on Thursday. Elevance Health has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The firm has a market capitalization of $76.81 billion, a PE ratio of 13.76, a P/E/G ratio of 1.88 and a beta of 0.51. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.56 and a current ratio of 1.54. The stock’s 50-day simple moving average is $351.69 and its 200-day simple moving average is $328.98.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. During the same quarter in the prior year, the firm earned $3.84 earnings per share. Elevance Health’s revenue for the quarter was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities analysts expect that Elevance Health will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be issued a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is currently 27.23%.

Institutional Investors Weigh In On Elevance Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Physician Wealth Advisors Inc. grew its holdings in Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after buying an additional 63 shares in the last quarter. Activest Wealth Management boosted its position in shares of Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after acquiring an additional 34 shares during the last quarter. Rossby Financial LCC grew its holdings in shares of Elevance Health by 110.0% in the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after purchasing an additional 44 shares during the period. Vermillion & White Wealth Management Group LLC increased its position in Elevance Health by 94.9% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after purchasing an additional 37 shares during the last quarter. Finally, BOK Financial Private Wealth Inc. purchased a new position in Elevance Health during the second quarter worth about $32,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 earnings beat consensus (EPS beat and strong profit print), which sparked an earlier rally and helped lift investor sentiment. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Leerink Partners nudged its price target up to $357 and maintained a “market perform” rating, a modest vote of confidence that signals upside potential from current levels. Leerink Partners adjusts price target on Elevance Health to $357
• Positive Sentiment: Consensus broker sentiment remains constructive (average “Moderate Buy”), which provides some support for the shares as analysts digest results and guidance. Elevance Health, Inc. Given Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Company Q4 call and published highlights provide detail on membership shifts, margin dynamics and the drivers behind the quarter — useful for longer-term modeling but not a clear immediate catalyst. ELV Q4 2025 Earnings Call Highlights
• Negative Sentiment: Management forecast for 2026 profit came in below some Street estimates and flagged an anticipated revenue decline, which is the principal near-term headwind pressuring the stock. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Analysts and commentary highlighted margin pressures and membership shifts shaping a weaker 2026 outlook — narratives that have driven selloffs despite the quarterly beat. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts
• Negative Sentiment: Regulatory context: a CMS proposal for only a modest Medicare Advantage rate increase added to near-term investor concern, contributing to a large negative move earlier in the week. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: Coverage pieces framed the results as “in line” but stressed the deteriorating outlook and ongoing industry headwinds, which has kept selling pressure on the shares after the initial post-earnings bounce. Elevance reports Q4 in line with expectations but stock drops

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.